Mirelli E, Fichera G, Volpe A D, Lasala M
Curr Med Res Opin. 1978;5(8):648-54. doi: 10.1185/03007997809110202.
A gastroscopic study was carried out in patients with rheumatic disorders to investigate the gastric tolerance of glucamethacin, a new, non-steroidal anti-inflammatory agent. The first stage was a double-blind crossover comparison of the effects of glucamethacin (420 mg/day) and indomethacin (100 mg/day), each given for 15 days in random order to 30 patients. In the second, open stage, 70 such patients, most of whom also had gastrointestinal pathology, received glucamethacin (420 mg/day) for 25 days. The results of endoscopic findings showed that significantly fewer (p less than 0.05) gastric lesions were produced after treatment with glucamethacin than after indomethacin. In the patients with gastro-duodenal pathology treated only with glucamethacin there was no change in endoscopy findings in 74% of the patients and only slight changes in the others.
对患有风湿性疾病的患者进行了一项胃镜研究，以调查一种新型非甾体抗炎药——葡甲胺的胃耐受性。第一阶段是对30名患者进行双盲交叉比较，随机顺序给予葡甲胺（420毫克/天）和吲哚美辛（100毫克/天），每种药物服用15天。在第二阶段的开放试验中，70名此类患者（其中大多数也有胃肠道病变）接受了25天的葡甲胺（420毫克/天）治疗。内镜检查结果显示，与吲哚美辛治疗后相比，葡甲胺治疗后产生的胃部病变明显更少（p<0.05）。在仅接受葡甲胺治疗的胃十二指肠病变患者中，74%的患者内镜检查结果无变化，其他患者仅有轻微变化。
